Annoviant

Annoviant is a private, pre-revenue medical device company developing the TxGuard™ regenerative tissue platform. The technology focuses on overcoming critical failures of existing biological implants—such as calcification, thrombosis, and degeneration—by creating decellularized, stabilized tissues that can be repopulated by the patient's own cells. Its initial pipeline targets pediatric and adult cardiovascular surgeries, with a pulmonary valved conduit for congenital heart disease as the lead program, supported by a $2.99M NIH grant. The company aims to reduce the need for repeat surgeries and improve long-term patient outcomes.

TxGuard™ is a patented tissue engineering platform involving decellularization of biological tissue, stabilization with proprietary chemistry, and a unique sterilization process. It creates regenerative, thrombo-resistant, and calcification-resistant scaffolds designed to be repopulated by the patient's own cells, allowing the implant to integrate and grow with the host.

Annoviant competes in the advanced tissue heart valve and vascular graft market against giants like Edwards Lifesciences, Medtronic, and Abbott, who are also investing in next-generation tissue technologies. It also faces competition from other regenerative medicine and tissue engineering startups. Its differentiation hinges on proving superior long-term performance and true host regeneration.